The FDA is moving to streamline the approval process for generic biologic drugs. What kinds of drugs are we talking about and how much of a price reduction could we see from this major change? We asked Dr. Fred Browne of Griffin Health. For the full FDA press release: https://www.fda.gov/news-events/press-announcements/fda-moves-accelerate-biosimilar-development-and-lower-drug-costs Image Courtesy of Griffin Health
 
								
		 
								